Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Mohit Narang, MD, Rafat Abonour, MD, Brian G. M. Durie, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, James W. Hardin, PhD, Sundar Jagannath, MD, Howard R. Terebelo, DO, Lynne Wagner, PhD, Shankar Srinivasan, PhD, E. Dawn Flick, MPH. ScD, Faiza Zafar, MPAS, Amani Kitali, MBA, MPH, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3156.

https://doi.org/10.1182/blood.V130.Suppl_1.3156.3156

Published: 2017

Journal Articles

Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect ® MM Registry

Cristina J. Gasparetto, MD, Rafat Abonour, MD, Sundar Jagannath, MD, Brian G. M. Durie, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, James W. Hardin, PhD, Lynne Wagner, PhD, Shankar Srinivasan, PhD, Amani Kitali, MBA, MPH, E. Dawn Flick, MPH, Faiza Zafar, MPAS, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3101.

https://doi.org/10.1182/blood.V130.Suppl_1.3101.3101

Published: 2017

Journal Articles

Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect ® MMpatient Registry

Sundar Jagannath, MD, Robert M. Rifkin, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, Brian G. M. Durie, MD, James W. Hardin, PhD, Howard R. Terebelo, DO, Lynne Wagner, PhD, Mohit Narang, MD, Shankar Srinivasan, PhD, Ahmed YoussefAgha, PhD, Amani Kitali, MBA, MPH, Gail Larkins, RN, MBA, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2017) 130 (Supplement 1): 3122.

https://doi.org/10.1182/blood.V130.Suppl_1.3122.3122

Published: 2017

Journal Articles

Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect ® MM Patient Registry

Howard R. Terebelo, DO, Rafat Abonour, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, Brian G. M. Durie, MD, James W. Hardin, PhD, Sundar Jagannath, MD, Lynne Wagner, PhD, Mohit Narang, MD, Shankar Srinivasan, PhD, Lihua Yue, PhD, Faiza Zafar, MPAS, Amani Kitali, MBA, MPH, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 1842.

https://doi.org/10.1182/blood.V130.Suppl_1.1842.1842

Published: 2017

Journal Articles

Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Wee J Chng, MD MRCP, FRCPATH, PhD, Kihyun Kim, MD PhD, Jeffrey Huang, Chor Sang Chim, MBChB, Hiroshi Kosugi, MD PhD, Naoki Takezako, MD PhD, Junichi Sakamoto, MD PhD, Sathish Kumar Gopalakrishnan, Yuan Wei, Ling Ying Zhuo, Je-Jung Lee, Sung-Soo Yoon, MD PhD, Jin Seok Kim, MD PhD, Chang-Ki Min, Jae-Hoon Lee, Brian G M Durie

Blood (2016) 128 (22): 2130.

https://doi.org/10.1182/blood.V128.22.2130.2130

Published: 2016

Journal Articles

Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care Therapies in Patients with Heavily Pre-Treated and Highly Refractory Multiple Myeloma

Shaji K. Kumar, MD, Brian G M Durie, Zhuo Su, Joris Diels, PhD, Brian Hutton, Annette Lam, Ito Tetsuro

Blood (2016) 128 (22): 4517.

https://doi.org/10.1182/blood.V128.22.4517.4517

Published: 2016

Journal Articles

Bortezomib Based Induction Is Superior to Thalidomide Based Induction in Reducing Early Relapses Following Upfront HDM: an Analysis By the Asian Myeloma Working Group

Sathish Kumar Gopalakrishnan, FRCPath, Shin-Yeu Ong, MD MRCP, MSE, Seok Jin Kim, Hae Su Kim, MD, Ji Yun Lee, Sung Hee Lim, Yunxin Chen, MBBS, MRCP, FRCPath, Sanjay De Mel, BSc, FRCPath, MRCP,, Melissa G. Ooi, Shilpa Surendran, MBBS, Adeline Lin, Daryl Tan, MBBS, MRCP, Brian G M Durie, Wee Joo Chng, MB ChB, MRCP, PhD, Kihyun Kim, MD PhD

Blood (2016) 128 (22): 4650.

https://doi.org/10.1182/blood.V128.22.4650.4650

Published: 2016

Journal Articles

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Blood (2016) 127 (24): 2955–2962.

https://doi.org/10.1182/blood-2016-01-631200

Published: 2016

Includes: Supplemental data

Journal Articles

Evaluation of Circulating Tumour DNA for the Mutational Characterisation of Multiple Myeloma

Andrew Spencer, Sridurga Mithraprabhu, Post doc, Malarmathy Ramachandran, Daniela Klarica, RN, Jay Hocking, MD, Laura Mai, Stephanie Walsh, David Broemeling, Andre Marziali, Anna Kalff, MD, Matthew Wiggin, Brian G. M. Durie, MD, Tiffany T. Khong, PhD

Blood (2015) 126 (23): 368.

https://doi.org/10.1182/blood.V126.23.368.368

Published: 2015

Journal Articles

Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN)

*Luzalba Sanoja-Flores, M.Sc., *Bruno Paiva, PhD, Juan A Flores-Montero, MD, Noemi Puig, MD PhD, Leire Burgos, Omar García, PhD, Felipe Prosper, MD, Juana Merino, MDPhD, Maria Belen Vidriales, MD PhD, Maria-Victoria Mateos, Ramon Garcia, MD, Luis Palomera, MDPhD, Rafael Rios, María Consuelo Cañizo, MD PhD, Brian G M Durie, Jacques J.M. van Dongen, Jesus San Miguel, MDPhD, Alberto Orfao, MD PhD

Blood (2015) 126 (23): 4180.

https://doi.org/10.1182/blood.V126.23.4180.4180

Published: 2015

Journal Articles

Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study

Blood (2015) 126 (23): 4201.

https://doi.org/10.1182/blood.V126.23.4201.4201

Published: 2015

Journal Articles

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

Jatin J. Shah, Edward A. Stadtmauer, Rafat Abonour, Adam D. Cohen, William I. Bensinger, Cristina Gasparetto, Jonathan L. Kaufman, Suzanne Lentzsch, Dan T. Vogl, Christina L. Gomes, Natalia Pascucci, David D. Smith, Robert Z. Orlowski, Brian G. M. Durie

Blood (2015) 126 (20): 2284–2290.

https://doi.org/10.1182/blood-2015-05-643320

Published: 2015

Journal Articles

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

Blood (2015) 125 (13): 2068–2074.

https://doi.org/10.1182/blood-2014-12-615187

Published: 2015

Includes: Supplemental data

Journal Articles

A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma

William I. Bensinger, MD, Robert Vescio, MD, Cristina Gasparetto, MD, Elber S. Camacho, MD, Rajneesh Nath, MD, Christina L. Gomes, MD, David D. Smith, PhD, Jatin J. Shah, Brian G. M. Durie, MD

Blood (2014) 124 (21): 4739.

https://doi.org/10.1182/blood.V124.21.4739.4739

Published: 2014

Journal Articles

A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Adam D. Cohen, MD, Emma C. Scott, MD, Michaela Liedtke, MD, Jonathan L. Kaufman, MD, Heather Landau, MD, David H. Vesole, MD PhD, Christina L. Gomes, MD, Cristina Gasparetto, MD, Suzanne Lentzsch, MD PhD, Michael Rosenzweig, MD, Vaishali Sanchorawala, MD, David D. Smith, PhD, Raymond L. Comenzo, MD, Brian G. M. Durie, MD

Blood (2014) 124 (21): 4741.

https://doi.org/10.1182/blood.V124.21.4741.4741

Published: 2014

Journal Articles

SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM)

Saad Z. Usmani, MD, Rachael Sexton, Sikander Ailawadhi, MD, Jatin J. Shah, Natalie S Callander, MD, Todd Zimmerman, MD, Jason Valent, MD, Michael Rosenzweig, MD, Brea C. Lipe, MD, Jeffrey Zonder, MD, Sandi Fredette, Brian G. M. Durie, MD, Antje Hoering, PhD, S. Vincent Rajkumar, MD, Paul G. Richardson, Robert Z. Orlowski, PhD MD

Blood (2014) 124 (21): 4762.

https://doi.org/10.1182/blood.V124.21.4762.4762

Published: 2014

Journal Articles

Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM)

Robert M. Rifkin, MD, Rafat Abonour, MD, Jatin J. Shah, MD, Jayesh Mehta, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Cristina J Gasparetto, MD, Sachdev P. Thomas, MD, Kathleen Toomey, MD, James W Hardin, PhD, Jane Jie Lu, MS, Laurie Kenvin, BSN, RN, Shankar Srinivasan, PhD, Rosanna J. Ricafort, MD, Yasir Nagarwala, MD, Brian G. M. Durie, MD

Blood (2014) 124 (21): 4749.

https://doi.org/10.1182/blood.V124.21.4749.4749

Published: 2014

Journal Articles

Impact of Novel Treatments on Multiple Myeloma Survival

David Robinson, Satyin Kaura, MSci, MBA, Daniel Kiely, Mohamad A. Hussein, MD, Knar Nersesyan, Brian G. M. Durie, MD

Blood (2014) 124 (21): 5676.

https://doi.org/10.1182/blood.V124.21.5676.5676

Published: 2014

Journal Articles

Connect MM ® —the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

Jatin J. Shah, MD, Rafat Abonour, MD, Brian G M Durie, MD, Jayesh Mehta, MD, Mohit Narang, MD, Howard Terebelo, DO, Cristina J Gasparetto, MD, Sachdev P. Thomas, MD, Kathleen Toomey, MD, James W Hardin, PhD, Shankar Srinivasan, PhD, Rosanna J. Ricafort, MD, Yasir Nagarwala, MD, Robert M. Rifkin, MD

Blood (2014) 124 (21): 2106.

https://doi.org/10.1182/blood.V124.21.2106.2106

Published: 2014

Journal Articles

Multiple Myeloma Profile In Latin America: Clinical and Epidemiological Observational Study

Blood (2013) 122 (21): 5327.

https://doi.org/10.1182/blood.V122.21.5327.5327

Published: 2013

NARROW

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect ® MM Registry

Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect ® MMpatient Registry

Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect ® MM Patient Registry

Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care Therapies in Patients with Heavily Pre-Treated and Highly Refractory Multiple Myeloma

Bortezomib Based Induction Is Superior to Thalidomide Based Induction in Reducing Early Relapses Following Upfront HDM: an Analysis By the Asian Myeloma Working Group

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Evaluation of Circulating Tumour DNA for the Mutational Characterisation of Multiple Myeloma

Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN)

Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma

A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis

SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM)

Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM)

Impact of Novel Treatments on Multiple Myeloma Survival

Connect MM ® —the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

Multiple Myeloma Profile In Latin America: Clinical and Epidemiological Observational Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only